Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs?

Bente Glintborg*, Rikke Ibsen, Rebecca Elisabeth Qwist Bilbo, Merete Lund Hetland, Jakob Kjellberg

*Corresponding author af dette arbejde
8 Citationer (Scopus)
1 Downloads (Pure)

Fingeraftryk

Dyk ned i forskningsemnerne om 'Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs?'. Sammen danner de et unikt fingeraftryk.

Medicin og biovidenskab